Cargando…

Evaluation of clinical efficacy of tumor necrosis factor‑α inhibitors in treatment of distal extremity swelling with pitting edema in psoriatic arthritis of inadequate response to conventional therapy: A 10‑year retrospective study

Distal extremity swelling with pitting edema in psoriatic arthritis (PsA) is a rare rheumatological condition, whose management presents a challenge. The aim of the present study was to identify the clinical characteristics of, and formulate a standardized management strategy for, patients with dist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Chenyang, Liu, Bingqian, Yao, Yuan, Yang, Kevin, Zang, Bo, Liu, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189727/ https://www.ncbi.nlm.nih.gov/pubmed/37206568 http://dx.doi.org/10.3892/etm.2023.11962

Ejemplares similares

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

A Case of Eosinophilic Fasciitis Presenting as Pitting Edema of the Lower Extremities
por: Lee, Hee Seon, et al.
Publicado: (2014)

Unusual Bilateral Upper Extremity Pitting Edema in a Patient With Severe Dermatomyositis
por: Mukkera, Srikanth, et al.
Publicado: (2021)

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
por: Nash, Peter, et al.
Publicado: (2018)

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Publicado: (2019)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
por: Mease, Philip J., et al.
Publicado: (2018)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
por: Strand, Vibeke, et al.
Publicado: (2019)

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists
por: Wu, Chun-Ying, et al.
Publicado: (2016)

Comparing the Clinical and Laboratory Features of Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Seronegative Rheumatoid Arthritis
por: Higashida-Konishi, Misako, et al.
Publicado: (2021)

Olanzapine-induced tender pitting pre-tibial edema
por: Mathan, Kaliaperumal, et al.
Publicado: (2015)

Swelling and Erythema of the Lower Extremities
por: Eaby-Sandy, Beth
Publicado: (2016)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
por: Kirkham, Bruce, et al.
Publicado: (2021)

Hand Erosive Osteoarthritis and Distal Interphalangeal Involvement in Psoriatic Arthritis: The Place of Conservative Therapy
por: Poletto, Elena, et al.
Publicado: (2021)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Quetiapine‐induced chest wall edema with the swellings of face and extremities in a young hospitalized patient: A case report
por: Elyasi, Forouzan, et al.
Publicado: (2023)

Depression led pitting edema: A rarest case presentation
por: Sapkota, Niraj Khatri
Publicado: (2017)

Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic
por: Sin, Chi-Zai, et al.
Publicado: (2019)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
por: Strand, Vibeke, et al.
Publicado: (2021)

A case of unilateral extremity swelling
por: Heberton, Meghan, et al.
Publicado: (2019)

Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2022)

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Caused by Crystal-Induced Arthritis of the Wrist: A Case Report
por: Hakozaki, Michiyuki, et al.
Publicado: (2013)

Comparing the Clinical and Laboratory Features of Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Seronegative Rheumatoid Arthritis: Stage 1
por: Higashida-Konishi, Misako, et al.
Publicado: (2021)

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
por: Zeng, Xiaofeng, et al.
Publicado: (2021)

Psoriatic Arthritis: An Update
por: Lloyd, Peter, et al.
Publicado: (2012)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Tongue swelling and necrosis after brain tumor surgery
por: Nimjee, Shahid M., et al.
Publicado: (2012)

Remitting seronegative symmetrical synovitis with pitting edema syndrome in maintenance hemodialysis
por: Matsugasumi, Toru, et al.
Publicado: (2020)

Remitting seronegative symmetrical synovitis with pitting edema: a case report
por: Tanaka, Yasushi, et al.
Publicado: (2022)

Generalized pitting edema in a patient with dilated cardiomyopathy secondary to hypothyroidism
por: Matsuura, Naoki, et al.
Publicado: (2023)

A Pilot Study of the Association of Tumor Necrosis Factor Alpha Polymorphisms with Psoriatic Arthritis in the Romanian Population
por: Popa, Olivia M., et al.
Publicado: (2011)

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis
por: Thorlund, Kristian, et al.
Publicado: (2012)

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
por: Rendas-Baum, Regina, et al.
Publicado: (2011)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qk7q1gnirrec1822h82tkv4s9j